No Result
View All Result
Success American Investors
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Success American Investors
No Result
View All Result
Home Stock

Semalytix’s PatientGPT to Reduce Six Months of Life Science Evidence & Insight Generation to Seconds

by
July 11, 2023
in Stock
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Semalytix, a life science startup based in Bielefeld, has announced the launch of PatientGPT, a large language model trained on global patient experience data for the life sciences. This new model is the first of its kind and provides a revolutionary approach to drug development.

The technology has been developed by Semalytix and can replace up to 6 months of research with seconds. It is able to analyse and interpret effects and value estimates of medications based on millions of patient experiences. Additionally, a range of safety measures and anonymization guidelines have been implemented to ensure the protection of sensitive patient data.

Co-founder and Chief Product Officer, Janik Jaskolski, said: “We can not only analyze but also precisely query the effects of any medication based on patient experiences and unmet needs worldwide, down to the smallest detail. By the end of the year, we will have over 50 million patient data points in our patient experience data archive, which our own LLM solution will be tuned with. This allows us to gain exact insights into how people live with diseases and generate crucial new knowledge for patient-focused drug development.”

Prof. Dr. Philipp Cimiano, co-founder and Chief Technology Officer of Semalytix, added: “PatientGPT truly unlocks the huge potential of patient experience data that will help shape new therapies and authentically and continuously answer what patients need most.”

Semalytix’s customers include many of the top 20 pharmaceutical companies worldwide. The technology is expected to dramatically accelerate the speed of therapy development and improve how well new drugs match patients’ needs.

Semalytix was founded in 2015 by managing directors Janik Jaskolski, Philipp Cimiano, and Matthias Hartung and currently employs 25 employees.

Today marks a new era in drug development with the announcement of PatientGPT, a large language model trained on global patient experience data for the life sciences. Developed by Bielefeld-based life science startup Semalytix, the model can replace up to 6 months of research with seconds and is capable of analysing and interpreting effects and value estimates of medications based on millions of patient experiences.

Co-founder and Chief Product Officer, Janik Jaskolski, said: “We can not only analyze but also precisely query the effects of any medication based on patient experiences and unmet needs worldwide, down to the smallest detail. By the end of the year, we will have over 50 million patient data points in our patient experience data archive, which our own LLM solution will be tuned with. This allows us to gain exact insights into how people live with diseases and generate crucial new knowledge for patient-focused drug development.”

Prof. Dr. Philipp Cimiano, co-founder and Chief Technology Officer of Semalytix, added: “PatientGPT truly unlocks the huge potential of patient experience data that will help shape new therapies and authentically and continuously answer what patients need most.”

Semalytix’s customers include many of the top 20 pharmaceutical companies worldwide and the technology is expected to dramatically accelerate the speed of therapy development and improve how well new drugs match patients’ needs.

Semalytix, a Bielefeld-based life science startup, has announced the launch of PatientGPT, a groundbreaking language model that uses supervised machine learning and large language models to provide critical accuracy for the life sciences industry.

The model is capable of analysing and interpreting effects and value estimates of medications based on millions of patient experiences in seconds, a task that would otherwise require up to 6 months of work. It also has access to over 100 million sources in 26 different languages, and can access real-time data.

Janik Jaskolski, co-founder and Chief Product Officer of Semalytix, said: “Our PatientGPT summarises thousands of patient voices and will give you an answer to this question, again and again. Billions of pieces of information about patient-centred experiences reveal entirely new opportunities for therapies and medication.”

Prof. Dr. Philipp Cimiano, co-founder and Chief Technology Officer of Semalytix, added: “We want to dramatically accelerate the speed of therapy development and improve how well new drugs match patients’ burdens. We contribute by making the global patient experience as accessible as possible in a compliant and ethical way.”

Semalytix was founded in 2015 by managing directors Janik Jaskolski, Philipp Cimiano, and Matthias Hartung and currently employs 25 employees. Its customers include many of the top 20 pharmaceutical companies worldwide.

The post Semalytix’s PatientGPT to Reduce Six Months of Life Science Evidence & Insight Generation to Seconds first appeared on BusinessMole.

Previous Post

to be held Discussions on Community Housing to Take Place

Next Post

Navigating Business Travel to China: Essential Tips and Considerations

Next Post

Navigating Business Travel to China: Essential Tips and Considerations

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest
Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

February 14, 2024
Idaho Bucks Managed Care Trend

Idaho Bucks Managed Care Trend

December 5, 2023

The Producer Price Index

September 9, 2023

CMKE Introduces PPM Subscription Model to Drive Cost Savings for Scottish Businesses

November 9, 2023
Bank of England governor urges UK to rebuild EU trade ties as key summit looms

Bank of England governor urges UK to rebuild EU trade ties as key summit looms

0

0

0

0
Bank of England governor urges UK to rebuild EU trade ties as key summit looms

Bank of England governor urges UK to rebuild EU trade ties as key summit looms

May 9, 2025
The Power of No: Why, When and How to Say It

The Power of No: Why, When and How to Say It

May 9, 2025

Building a SaaS Marketing Strategy That Scales Without Burning Through Your Budget

May 9, 2025
US trade deal is not a win for UK automotive industry

US trade deal is not a win for UK automotive industry

May 9, 2025

Recent News

Bank of England governor urges UK to rebuild EU trade ties as key summit looms

Bank of England governor urges UK to rebuild EU trade ties as key summit looms

May 9, 2025
The Power of No: Why, When and How to Say It

The Power of No: Why, When and How to Say It

May 9, 2025

Building a SaaS Marketing Strategy That Scales Without Burning Through Your Budget

May 9, 2025
US trade deal is not a win for UK automotive industry

US trade deal is not a win for UK automotive industry

May 9, 2025

Disclaimer: SuccessAmericanInvestors.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.